<!DOCTYPE html>



<html lang="en">



	<meta charset="UTF-8">

	<meta name="viewport" content="width=device-width, initial-scale=1.0">

	<style>


    .node {

        stroke: #fff;

        stroke-width: 2px;

    }

    

    .link {

        stroke: #777;

        stroke-width: 2px;

    }



</style>

<body>

<a href="https://riskrunners.com">Home</a><br>




<a href="#risk_factors">Jump to Risk Factors</a><br>



<a href="#industry">Jump to Industries</a><br>


<a href="#exposure">Jump to Exposures</a><br>


<a href="#event_code">Jump to Event Codes</a><br>


<a href="#wiki">Jump to Wiki Summary</a><br><br>


    <script src="https://d3js.org/d3.v3.min.js"></script>

    <script>


// set a width and height for our SVG

var width = 3000,


    height = 3000;

    
// setup links

var links =     [
{source: "START_HERE", target: "6: product discovery", fill: "#536878"},
{source: "6: product discovery", target: "6: development", fill: "#536878"},
{source: "6: development", target: "6: money prior", fill: "#536878"},
{source: "6: money prior", target: "6: commercialization", fill: "#536878"},
{source: "6: product discovery", target: "16: development", fill: "#fc0"},
{source: "16: development", target: "16: significant", fill: "#fc0"},
{source: "16: significant", target: "16: additional", fill: "#fc0"},
{source: "16: additional", target: "16: regulatory", fill: "#fc0"},
{source: "16: regulatory", target: "16: commitment", fill: "#fc0"},
{source: "16: commitment", target: "16: significant additional resources prior", fill: "#fc0"},
{source: "16: significant additional resources prior", target: "16: commercialization", fill: "#fc0"},
{source: "16: development", target: "19: future capital requirements will", fill: "#009e60"},
{source: "19: future capital requirements will", target: "19: depend on", fill: "#009e60"},
{source: "19: depend on", target: "19: factors such as", fill: "#009e60"},
{source: "19: factors such as", target: "19: existing collaborative relationships", fill: "#009e60"},
{source: "19: existing collaborative relationships", target: "19: additional collaborative arrangements", fill: "#009e60"},
{source: "19: additional collaborative arrangements", target: "19: continued scientific", fill: "#009e60"},
{source: "19: continued scientific", target: "19: research drug discovery", fill: "#009e60"},
{source: "19: research drug discovery", target: "19: development programs", fill: "#009e60"},
{source: "19: development programs", target: "19: with preclinical", fill: "#009e60"},
{source: "19: with preclinical", target: "19: costs involved", fill: "#009e60"},
{source: "19: costs involved", target: "19: regulatory approvals", fill: "#009e60"},
{source: "19: regulatory approvals", target: "19: competing technological", fill: "#009e60"},
{source: "19: competing technological", target: "19: market developments", fill: "#009e60"},
{source: "19: market developments", target: "19: introduction by others", fill: "#009e60"},
{source: "19: introduction by others", target: "19: new therapies", fill: "#009e60"},
{source: "19: new therapies", target: "19: commercializing", fill: "#009e60"},
{source: "19: commercializing", target: "19: based on", fill: "#009e60"},
{source: "19: based on", target: "19: infectious organisms", fill: "#009e60"},
{source: "19: infectious organisms", target: "19: launch timing", fill: "#009e60"},
{source: "19: future capital requirements will", target: "32: enter into", fill: "#fbab60"},
{source: "32: enter into", target: "32: collaborations", fill: "#fbab60"},
{source: "32: collaborations", target: "32: development activities", fill: "#fbab60"},
{source: "32: development activities", target: "32: manufacturing by third parties", fill: "#fbab60"},
{source: "32: manufacturing by third parties", target: "32: regulatory", fill: "#fbab60"},
{source: "32: regulatory", target: "32: clinical trials", fill: "#fbab60"},
{source: "32: clinical trials", target: "32: Successfully ", fill: "#fbab60"},
{source: "32: Successfully ", target: "32: commercialize existing", fill: "#fbab60"},
{source: "32: commercialize existing", target: "32: future products", fill: "#fbab60"},
{source: "32: enter into", target: "39: significant financial support from", fill: "#f2f3f4"},
{source: "39: significant financial support from", target: "39: development", fill: "#f2f3f4"},
{source: "39: development", target: "39: TIGER ", fill: "#f2f3f4"},
{source: "39: TIGER ", target: "39: biosensor system", fill: "#f2f3f4"},
{source: "39: significant financial support from", target: "42: technologies", fill: "#ffddf4"},
{source: "42: technologies", target: "42: collaboration with others", fill: "#ffddf4"},
{source: "42: collaboration with others", target: "42: competitors", fill: "#ffddf4"},
{source: "42: competitors", target: "42: treatments", fill: "#ffddf4"},
{source: "42: treatments", target: "42: same diseases targeted by", fill: "#ffddf4"},
{source: "42: same diseases targeted by", target: "42: collaborative programs", fill: "#ffddf4"},
{source: "42: technologies", target: "129: market acceptance", fill: "#f0ead6"},
{source: "129: market acceptance", target: "129: products depends upon", fill: "#f0ead6"},
{source: "129: products depends upon", target: "129: regulatory approvals", fill: "#f0ead6"},
{source: "129: regulatory approvals", target: "129: establishment", fill: "#f0ead6"},
{source: "129: establishment", target: "129: demonstration", fill: "#f0ead6"},
{source: "129: demonstration", target: "129: community", fill: "#f0ead6"},
{source: "129: community", target: "129: advantages over competing products", fill: "#f0ead6"},
{source: "129: advantages over competing products", target: "129: effectiveness", fill: "#f0ead6"},
{source: "129: effectiveness", target: "129: drugs compared", fill: "#f0ead6"},
{source: "129: drugs compared", target: "129: patient convenience", fill: "#f0ead6"},
{source: "129: patient convenience", target: "129: dosing regimen", fill: "#f0ead6"},
{source: "129: dosing regimen", target: "129: Reimbursement ", fill: "#f0ead6"},
{source: "129: Reimbursement ", target: "129: government", fill: "#f0ead6"},
{source: "129: government", target: "129: third party payers", fill: "#f0ead6"},
{source: "129: market acceptance", target: "START_HERE", fill: "#f0ead6"}]; 
    // create empty nodes array
    var nodes = {};
	var colorFill = [];
	
    // compute nodes from links data
    links.forEach(function(link) {
        link.source = nodes[link.source] ||
            (nodes[link.source] = {name: link.source});
        link.target = nodes[link.target] ||
            (nodes[link.target] = {name: link.target});
		colorFill.push({name: link.source.name, fill: link.fill });
		colorFill.push({name: link.target.name, fill: link.fill });
    });
	
	console.log(colorFill);


    // add a SVG to the body for our viz
    var svg=d3.select('body').append('svg')
        .attr("viewBox", "0 0 " + width + " " + height );

    // use the force
    var force = d3.layout.force()
		.charge(-5000)
		.gravity(0.3)
        .size([width, height])
        .nodes(d3.values(nodes))
        .links(links)
        .on("tick", tick)
        .linkDistance(200)
        .start();

    // add links
    var link = svg.selectAll('.link')
        .data(links)
        .enter().append('line')
        .attr('class', 'link'); 

    // add nodes
    var node = svg.selectAll('.node')
        .data(force.nodes())
        .enter().append('circle')
        .attr('class', 'node')
        .attr('r', width * 0.0035)
		.style("fill", function(d) {
									for (var i = 0; i < colorFill.length; i++) {
										//console.log(d.name);
										if(colorFill[i].name == d.name){
											console.log(colorFill[i].fill);
											return colorFill[i].fill;
										}
									} return "#555";
									
									});
	var label = svg.selectAll(null)
		.data(force.nodes())
		.enter()
		.append("text")
		.text(function (d) { return d.name; })
		.style("text-anchor", "middle")
		.style("fill", "#555")
		.style("font-family", "Arial")
		.style("font-size", 34);


    // what to do 
    function tick(e) {
        
        node.attr('cx', function(d) { return d.x = Math.max(6, Math.min(width - 6, d.x)); })
            .attr('cy', function(d) { return d.y = Math.max(6, Math.min(height - 6, d.y)); })
            .call(force.drag);
            
        link.attr('x1', function(d) { return d.source.x; })
            .attr('y1', function(d) { return d.source.y; })
            .attr('x2', function(d) { return d.target.x; })
            .attr('y2', function(d) { return d.target.y; });
		
		label.attr("x", function(d){ return d.x; })
             .attr("y", function (d) {return d.y - 10; });
        
    }
    
</script><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='industry'>Industries</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Investment Banking and Brokerage</td>
    </tr>
    <tr>
      <td>Technology Hardware Storage and Peripherals</td>
    </tr>
    <tr>
      <td>Information Technology</td>
    </tr>
    <tr>
      <td>Technology Hardware and Equipment</td>
    </tr>
    <tr>
      <td>Pharmaceuticals Biotechnology and Life Sciences</td>
    </tr>
    <tr>
      <td>Biotechnology</td>
    </tr>
    <tr>
      <td>Application Software</td>
    </tr>
    <tr>
      <td>Asset Management and Custody Banks</td>
    </tr>
    <tr>
      <td>Health Care Facilities</td>
    </tr>
    <tr>
      <td>Automobile Manufacturers</td>
    </tr>
    <tr>
      <td>Motorcycle Manufacturers</td>
    </tr>
    <tr>
      <td>Electronic Equipment and Instruments</td>
    </tr>
    <tr>
      <td>Health Care Distribution and Services</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='exposure'>Exposures</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Military</td>
    </tr>
    <tr>
      <td>Express intent</td>
    </tr>
    <tr>
      <td>Intelligence</td>
    </tr>
    <tr>
      <td>Judicial</td>
    </tr>
    <tr>
      <td>Provide</td>
    </tr>
    <tr>
      <td>Ease</td>
    </tr>
    <tr>
      <td>Political reform</td>
    </tr>
    <tr>
      <td>Regime</td>
    </tr>
    <tr>
      <td>Cooperate</td>
    </tr>
    <tr>
      <td>Leadership</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='event_code'>Event Codes</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Military blockade</td>
    </tr>
    <tr>
      <td>Acknowledge responsibility</td>
    </tr>
    <tr>
      <td>Solicit support</td>
    </tr>
    <tr>
      <td>Agree</td>
    </tr>
    <tr>
      <td>Accident</td>
    </tr>
    <tr>
      <td>Warn</td>
    </tr>
    <tr>
      <td>Promise</td>
    </tr>
    <tr>
      <td>Vote</td>
    </tr>
    <tr>
      <td>Sports contest</td>
    </tr>
    <tr>
      <td>Force</td>
    </tr>
    <tr>
      <td>Psychological state</td>
    </tr>
    <tr>
      <td>Yield to order</td>
    </tr>
    <tr>
      <td>Request</td>
    </tr>
    <tr>
      <td>Complain</td>
    </tr>
    <tr>
      <td>Demand</td>
    </tr>
    <tr>
      <td>Grant</td>
    </tr>
    <tr>
      <td>Riot</td>
    </tr>
    <tr>
      <td>Release or return</td>
    </tr>
    <tr>
      <td>Adjust</td>
    </tr>
    <tr>
      <td>Yield position</td>
    </tr>
    <tr>
      <td>Reject</td>
    </tr>
    <tr>
      <td>Yield</td>
    </tr>
    <tr>
      <td>Endorse</td>
    </tr>
    <tr>
      <td>Consult</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='wiki'>Wiki</th>
      <th>Wiki Summary</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Arrested_Development">Arrested Development</a></td>
      <td>Arrested Development is an American television sitcom created by Mitchell Hurwitz, which originally aired on Fox for three seasons from  2003 to 2006, followed by a two-season revival on Netflix from 2013 to 2019. The show follows the Bluths, a formerly wealthy dysfunctional family.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Development/For!">Development/For!</a></td>
      <td>Development/For! (Latvian: Attīstībai/Par!, AP!) is a liberal political alliance in Latvia.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Software_development">Software development</a></td>
      <td>Software development is the process of conceiving, specifying, designing, programming, documenting, testing, and bug fixing involved in creating and maintaining applications, frameworks, or other software components. Software development involves writing and maintaining the source code, but in a broader sense, it includes all processes from the conception of the desired software through to the final manifestation of the software, typically in a planned and structured process.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Commercialization">Commercialization</a></td>
      <td>Commercialization or commercialisation is the process of introducing a new product or production method into commerce—making it available on the market. The term often connotes especially entry into the mass market (as opposed to entry into earlier niche markets), but it also includes a move from the laboratory into (even limited) commerce.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Renewable_energy_commercialization">Renewable energy commercialization</a></td>
      <td>Renewable energy commercialization involves the deployment of three generations of renewable energy technologies dating back more than 100 years. First-generation technologies, which are already mature and economically competitive, include biomass, hydroelectricity, geothermal power and heat.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Commercialization_of_love">Commercialization of love</a></td>
      <td>The notion of commercialization of love, that is not to be confused with prostitution (the commercialization of sexual activity), involves the definitions of romantic love and consumerism.\n\n\n== Sociological development ==\nThe commercialization of love is the ongoing process of infiltration of commercial and economical stimuli in the daily life of lovers and the association of monetary and non-monetary symbols and commodities in the love relationships.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Commercial_use_of_space">Commercial use of space</a></td>
      <td>Commercial use of space is the provision of goods or services of commercial value by using equipment sent into Earth orbit or outer space.  This phenomenon – aka Space Economy (or New Space Economy) – is accelerating cross-sector innovation processes combining the most advanced space and digital technologies to develop a broad portfolio of space-based services.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Regulatory_state">Regulatory state</a></td>
      <td>The term regulatory state refers to the expansion in the use of rulemaking, monitoring and enforcement techniques and institutions by the state and to a parallel change in the way its positive or negative functions in society are being carried out. The expansion of the state nowadays is generally via regulation and less via taxing and spending.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Regulatory_sequence">Regulatory sequence</a></td>
      <td>A regulatory sequence is a segment of a nucleic acid molecule which is capable of increasing or decreasing the expression of specific genes within an organism. Regulation of gene expression is an essential feature of all living organisms and viruses.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Regulatory_law">Regulatory law</a></td>
      <td>Regulatory law refers to secondary legislation, including regulations, promulgated by an executive branch agency under a delegation from a legislature. It contrasts with statutory law promulgated by the legislative branch, and common law or case law promulgated by the judicial branch.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Phases_of_clinical_research">Phases of clinical research</a></td>
      <td>The phases of clinical research are the stages in which scientists conduct experiments with a health intervention to obtain sufficient evidence for a process considered effective as a medical treatment. For drug development, the clinical phases start with testing for safety in a few human subjects, then expand to many study participants (potentially tens of thousands) to determine if the treatment is effective.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Clinical_trial">Clinical trial</a></td>
      <td>Clinical trials are experiments or observations done in clinical research. Such prospective biomedical or behavioral research studies on human participants are designed to answer specific questions about biomedical or behavioral interventions, including new treatments (such as novel vaccines, drugs, dietary choices, dietary supplements, and medical devices) and known interventions that warrant further study and comparison.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/ClinicalTrials.gov">ClinicalTrials.gov</a></td>
      <td>ClinicalTrials.gov is a registry of clinical trials. It is run by the United States National Library of Medicine (NLM) at the National Institutes of Health, and is the largest clinical trials database, holding registrations from over 329,000 trials from 209 countries.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Randomized_controlled_trial">Randomized controlled trial</a></td>
      <td>A randomized controlled trial (or randomized control trial; RCT) is a form of scientific experiment used to control factors not under direct experimental control. Examples of RCTs are clinical trials that compare the effects of drugs, surgical techniques, medical devices, diagnostic procedures or other medical treatments.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Pragmatic_clinical_trial">Pragmatic clinical trial</a></td>
      <td>A pragmatic clinical trial (PCT), sometimes called a practical clinical trial (PCT), is a clinical trial that focuses on correlation between treatments and outcomes in real-world health system practice rather than focusing on proving causative explanations for outcomes, which requires extensive deconfounding with inclusion and exclusion criteria so strict that they risk rendering the trial results irrelevant to much of real-world practice.\n\n\n== Examples ==\nA typical example is that an anti-diabetic medication in the real world will often be used in people with (latent or apparent) diabetes-induced kidney problems, but if a study of its efficacy and safety excluded some subsets of people with kidney problems (to escape confounding), the study's results may not reflect well what will actually happen in broad practice.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Monitoring_in_clinical_trials">Monitoring in clinical trials</a></td>
      <td>Clinical monitoring is the oversight and administrative efforts that monitor a participant's health and efficacy of the treatment during a clinical trial. Both independent and government-run grant-funding agencies, such as the National Institutes of Health (NIH) and the World Health Organization (WHO), require data and safety monitoring protocols for Phase I and II clinical trials conforming to their standards.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Clinical_trials_in_India">Clinical trials in India</a></td>
      <td>Clinical trials in India refers to clinical research in India in which researchers test drugs and other treatments on research participants. NDCTR 2019 and section 3.7.1 to 3.7.3 of ICMR guidelines requires that all researchers conducting a clinical trial must publicly document it in the Clinical Trials Registry - India.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Clinical_trials_on_Ayurveda">Clinical trials on Ayurveda</a></td>
      <td>Clinical trials on Ayurveda refers to any clinical trials done on Ayurvedic treatment. Ayurveda is a traditional medicine system in India and like other cultural medical practices includes both conventional medicine and also complementary and alternative medicine.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Petroleum_microbiology">Petroleum microbiology</a></td>
      <td>Petroleum microbiology is a branch of microbiology that deals with the study of microorganisms that can metabolize or alter crude or refined petroleum products. These microorganisms, also called hydrocarbonoclastic microorganisms, can degrade hydrocarbons and, include a wide distribution of bacteria, methanogenic archaea, and some fungi.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Cell_counting">Cell counting</a></td>
      <td>Cell counting is any of various methods for the counting or similar quantification of cells in the life sciences, including medical diagnosis and treatment. It is an important subset of cytometry, with applications in research and clinical practice.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Bio-layer_interferometry">Bio-layer interferometry</a></td>
      <td>Bio-layer interferometry (BLI) is an optical biosensing technology that analyzes biomolecular interactions in real-time without the need for fluorescent labeling. Alongside Surface Plasmon Resonance, BLI is one of few widely available label-free biosensing technologies, a detection style that yields more information in less time than traditional processes.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Mesoporous_silica">Mesoporous silica</a></td>
      <td>Mesoporous silica is a mesoporous form of silica and a recent development in nanotechnology. The most common types of mesoporous nanoparticles are MCM-41 and SBA-15.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Microfluidics">Microfluidics</a></td>
      <td>Microfluidics refers to the behavior, precise control, and manipulation of fluids that are geometrically constrained to a small scale (typically sub-millimeter) at which surface forces dominate volumetric forces. It is a multidisciplinary field that involves engineering, physics, chemistry, biochemistry, nanotechnology, and biotechnology.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/IRIS_(biosensor)">IRIS (biosensor)</a></td>
      <td>Interferometric reflectance imaging sensor (IRIS), formerly known as the spectral reflectance imaging biosensor (SRIB), is a system that can be used as a biosensing platform capable of high-throughput multiplexing of protein–protein, protein–DNA, and DNA–DNA  interactions without the use of any fluorescent labels. The sensing surface is prepared by robotic spotting of biological probes that are immobilized on functionalized Si/SiO2 substrates.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Competition">Competition</a></td>
      <td>Competition is a rivalry where two or more parties strive for a common goal which cannot be shared: where one's gain is the other's loss (an example of which is a zero-sum game). Competition can arise between entities such as organisms, individuals, economic and social groups, etc.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Competitor_analysis">Competitor analysis</a></td>
      <td>Competitive analysis in marketing and strategic management is an assessment of the strengths and weaknesses of current and potential competitors. This analysis provides both an offensive and defensive strategic context to identify opportunities and threats.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Competitor_backlinking">Competitor backlinking</a></td>
      <td>Competitor backlinking is a search engine optimization strategy that involves analyzing the backlinks of competing websites within a vertical search. The outcome of this activity is designed to increase organic search engine rankings and to gain an understanding of the link building strategies used by business competitors.By analyzing the backlinks to competitor websites, it is possible to gain a benchmark on the number of links and the quality of links that is required for high search engine rankings.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Sport_of_athletics">Sport of athletics</a></td>
      <td>Athletics is a group of sporting events that involves competitive running, jumping, throwing, and walking. The most common types of athletics competitions are track and field, road running, cross country running, and racewalking.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Competitor_Group">Competitor Group</a></td>
      <td>Competitor Group, Inc. (CGI) is a privately held, for-profit, sports marketing and management company based in Mira Mesa, San Diego, California.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Round-robin_tournament">Round-robin tournament</a></td>
      <td>A round-robin tournament (or all-play-all tournament) is a competition in which each contestant meets every other participant, usually in turn. A round-robin contrasts with an elimination tournament, in which participants are eliminated after a certain number of losses.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Government_of_India">Government of India</a></td>
      <td>The Government of India (ISO: Bhārat Sarkār) (often abbreviated as GoI; also known as the Central or Union Government), or simply the Centre, is the federal governing authority of the Republic of India created by the Constitution of India as the legislative, executive and judicial authority to govern the union of twenty eight states and eight union territories. The president acts as the head of state and is the highest figure of authority, nominally, of the nation however it is the prime minister who is the chief executive.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Executive_(government)">Executive (government)</a></td>
      <td>The executive (short for executive branch or executive power) is the part of government that enforces law, and has responsibility for the governance of a state.\nIn political systems based on the principle of separation of powers, authority is distributed among several branches (executive, legislative, judicial)—an attempt to prevent the concentration of power in the hands of a single group of people.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Military_government">Military government</a></td>
      <td>A military government is generally any government that is administered by military forces, whether or not this government is legal under the laws of the jurisdiction at issue, and whether this government is formed by natives or by an occupying power. It is usually carried out by military workers.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Borne_government">Borne government</a></td>
      <td>The Borne government is the forty-third and current government of the French Fifth Republic, formed on 16 May 2022 and headed by Élisabeth Borne as Prime Minister under the presidency of Emmanuel Macron.\n\n\n== Context ==\n\n\n=== Formation ===\nOn 16 May 2022, Jean Castex tendered the resignation of his government to the President of the Republic.</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='risk_factors'>Risk Factors</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>In addition to     the other information in this report on Form 10-K, you <font color="blue">should carefully</font>     consider the <font color="blue">risks described</font> below before purchasing our securities</td>
    </tr>
    <tr>
      <td>If any     of the <font color="blue">following risks actually</font> occur, our business could be <font color="blue">materially</font>     harmed, and our <font color="blue">financial condition</font> and results of <font color="blue"><font color="blue">operations</font> could</font> be     <font color="blue">materially</font> and <font color="blue">adversely affected</font></td>
    </tr>
    <tr>
      <td>As a result, the <font color="blue">trading price</font> of our     securities could decline, and you might lose all or part of your <font color="blue">investment</font></td>
    </tr>
    <tr>
      <td><font color="blue">Risks Associated </font>with our <font color="blue">Businesses </font>as a Whole       We have <font color="blue">incurred losses</font>, and our business will suffer if we fail to achieve     <font color="blue">profitability</font> in the future</td>
    </tr>
    <tr>
      <td>Because <font color="blue">product <font color="blue">discovery</font></font> and <font color="blue">development</font> require substantial lead-time and     <font color="blue">money prior</font> to <font color="blue">commercialization</font>, our expenses have exceeded our revenue     since we were founded in January 1989</td>
    </tr>
    <tr>
      <td><font color="blue">As of <font color="blue">December </font></font>31, 2005, we had     <font color="blue">accumulated losses</font> of approximately dlra770dtta8 million and <font color="blue">stockholders</font>’ equity     of  approximately dlra2dtta7 million</td>
    </tr>
    <tr>
      <td>Most of the losses resulted from costs     incurred in <font color="blue">connection with</font> our research and <font color="blue">development</font> programs and from     general and <font color="blue">administrative costs associated with</font> our <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>Most of our     revenue has come from <font color="blue">collaborative</font> <font color="blue">arrangements</font>, with <font color="blue">additional</font> revenue     from  interest income and research grants and the sale or licensing of     patents</td>
    </tr>
    <tr>
      <td>We  currently have <font color="blue">only one product</font>, Vitravene, approved for     <font color="blue">commercial use</font></td>
    </tr>
    <tr>
      <td>This product has limited <font color="blue">sales potential</font></td>
    </tr>
    <tr>
      <td>We expect to incur     <font color="blue">additional</font> operating losses over the <font color="blue">next several years</font>, and these losses     may  increase  if  we  cannot  increase or <font color="blue">sustain revenue</font></td>
    </tr>
    <tr>
      <td>We may not     <font color="blue">successfully</font> develop any <font color="blue">additional</font> products or services, or achieve or     sustain future <font color="blue">profitability</font></td>
    </tr>
    <tr>
      <td>If we fail to obtain <font color="blue">timely funding</font>, we may need to curtail or abandon some     of our programs</td>
    </tr>
    <tr>
      <td>All of our product <font color="blue">candidates</font> are undergoing <font color="blue"><font color="blue">clinical trial</font>s</font> or are in the     early  stages  of  research and <font color="blue">development</font></td>
    </tr>
    <tr>
      <td>All of our products under     <font color="blue">development</font> will require <font color="blue">significant</font> <font color="blue">additional</font> research, <font color="blue">development</font>,     preclinical and/or clinical testing, <font color="blue">regulatory</font> approval and a <font color="blue">commitment</font> of     <font color="blue">significant</font> <font color="blue">additional</font> resources prior to their <font color="blue">commercialization</font></td>
    </tr>
    <tr>
      <td>Based on     our current operating plan <font color="blue">with reasonable <font color="blue">assumptions</font></font> for new sources of     revenue and cash, we believe our <font color="blue">resources will</font> be sufficient to meet our     anticipated <font color="blue">requirements</font> at least through 2007</td>
    </tr>
    <tr>
      <td>If we do not meet our goals     to <font color="blue">commercialize</font> our products,       31     ______________________________________________________________________       or  to  license  our  drugs and <font color="blue">proprietary <font color="blue">technologies</font></font>, we will need     <font color="blue">additional</font> funding in the future</td>
    </tr>
    <tr>
      <td>Our <font color="blue">future capital <font color="blue">requirements</font> will</font>     <font color="blue">depend on</font> many factors, such as the following:       ·        changes in existing <font color="blue">collaborative</font> relationships and our ability to     establish and maintain <font color="blue">additional</font> <font color="blue">collaborative</font> <font color="blue">arrangements</font>;       ·        <font color="blue">continued scientific</font> progress in our research, drug <font color="blue">discovery</font> and     <font color="blue">development</font> programs;       ·        the size of our programs and progress <font color="blue">with preclinical</font> and clinical     trials;       ·        the time and <font color="blue">costs involved</font> in obtaining <font color="blue">regulatory</font> approvals;       ·        <font color="blue">competing technological</font> and market <font color="blue">development</font>s, including the     <font color="blue"><font color="blue">introduction</font> by others</font> of <font color="blue">new therapies</font> that address our markets;       ·        success in developing and <font color="blue">commercializing</font> a business <font color="blue">based on</font> our     TIGER system to identify <font color="blue"><font color="blue">infectious organism</font>s</font>; and       ·        the profile and <font color="blue">launch timing</font> of our drugs</td>
    </tr>
    <tr>
      <td>If we need <font color="blue">additional</font> funds, we may need to <font color="blue">raise them through public</font> or     <font color="blue">private financing</font></td>
    </tr>
    <tr>
      <td><font color="blue">Additional </font><font color="blue">financing may</font> not be <font color="blue">available at</font> all or on     acceptable  terms</td>
    </tr>
    <tr>
      <td>In addition, if our <font color="blue">stockholders</font> do not approve an     increase in our <font color="blue">authorized capital stock</font>, it may limit our ability to raise     funds</td>
    </tr>
    <tr>
      <td>If we raise <font color="blue">additional</font> funds by issuing equity securities, the shares     of existing <font color="blue">stockholders</font> will be diluted and their price, as well as the     price  of our other securities, may decline</td>
    </tr>
    <tr>
      <td>If <font color="blue">adequate funds</font> are not     available, or not <font color="blue">available on</font> acceptable terms, we may have to cut back on     one or more of our research, drug <font color="blue">discovery</font> or <font color="blue">development</font> programs</td>
    </tr>
    <tr>
      <td>For     example, in January 2005 we decided to terminate the <font color="blue">development</font> of two     <font color="blue">lower priority drugs</font>, ISIS 14803 and ISIS 104838</td>
    </tr>
    <tr>
      <td>Alternatively, we may     obtain funds through <font color="blue">arrangements</font> with <font color="blue">collaborative</font> partners or others,     <font color="blue">which could</font> require us to <font color="blue">give up rights</font> to certain of our <font color="blue">technologies</font>,     product <font color="blue">candidates</font> or products</td>
    </tr>
    <tr>
      <td>If any of our <font color="blue">collaborative</font> <font color="blue">partners fail</font> to fund our <font color="blue">collaborative</font> programs     or develop or sell any of our products under <font color="blue">development</font>, or if we cannot     obtain <font color="blue">additional</font> partners, we may have to delay or stop progress on our     product <font color="blue">development</font> programs</td>
    </tr>
    <tr>
      <td>To date, corporate partnering has played a key role in our strategy to fund     our <font color="blue">development</font> programs and to add key <font color="blue">development</font> resources</td>
    </tr>
    <tr>
      <td>We plan to     continue to rely on <font color="blue">additional</font> <font color="blue">collaborative</font> <font color="blue">arrangements</font> to develop and     <font color="blue">commercialize</font>  our  products</td>
    </tr>
    <tr>
      <td>However, we may not be able to negotiate     <font color="blue">additional</font> attractive <font color="blue">collaborative</font> <font color="blue">arrangements</font>, and, even if negotiated,     the <font color="blue">collaborative</font> <font color="blue">arrangements</font> may not be successful</td>
    </tr>
    <tr>
      <td>We  have entered into <font color="blue">collaborative</font> <font color="blue">arrangements</font> with <font color="blue">third parties</font> to     develop many of our product <font color="blue">candidates</font></td>
    </tr>
    <tr>
      <td>We <font color="blue">enter into</font> these <font color="blue">collaborations</font>     in order to:       ·        Fund our research and <font color="blue">development</font> <font color="blue">activities</font>;       ·        Access <font color="blue"><font color="blue">manufacturing</font> by <font color="blue">third parties</font></font>;       ·        Seek and obtain <font color="blue">regulatory</font> approvals;       ·        Conduct <font color="blue"><font color="blue">clinical trial</font>s</font>; and       ·        <font color="blue">Successfully </font><font color="blue">commercialize</font> existing and <font color="blue">future products</font></td>
    </tr>
    <tr>
      <td>If any of our <font color="blue"><font color="blue">partners fail</font>s</font> to develop or sell any drug in which we have     retained a <font color="blue">financial interest</font>, our business may suffer</td>
    </tr>
    <tr>
      <td>These <font color="blue">collaborations</font>     may not continue or result in <font color="blue">commercialize</font>d drugs</td>
    </tr>
    <tr>
      <td>Our <font color="blue">collaborators</font> can     terminate their <font color="blue">relationships with us under certain circumstances</font>, some of     which are outside of our control</td>
    </tr>
    <tr>
      <td>For example, in November 2004 <font color="blue">based on</font> the     outcome  of  both Phase 3 trials, Lilly <font color="blue"><font color="blue">discontinue</font>d</font> its <font color="blue">investment</font> in     Affinitak</td>
    </tr>
    <tr>
      <td>32     ______________________________________________________________________       Other drugs in our <font color="blue">development</font> pipeline are being developed and/or funded by     corporate  partners,  including  <font color="blue">Antisense </font> Therapeutics  Limited, iCo     Therapeutics, Inc, OncoGenex Technologies Inc</td>
    </tr>
    <tr>
      <td>We have received     <font color="blue">significant</font> financial support from <font color="blue">United States </font>Government-funded grants     and  contracts  for our Ibis division and the <font color="blue">development</font> of our <font color="blue">TIGER     </font><font color="blue"><font color="blue">biosensor</font> system</font></td>
    </tr>
    <tr>
      <td><font color="blue">The <font color="blue">United States </font>Government </font>can <font color="blue">unilaterally terminate</font>     these contracts and <font color="blue">grants at</font> its <font color="blue">convenience at</font> any time, even if we have     fully performed our <font color="blue">obligations</font></td>
    </tr>
    <tr>
      <td>If any of these <font color="blue"><font color="blue">pharmaceutical</font> companies</font> or     <font color="blue">government</font> partners stopped funding and/or developing these products, our     business <font color="blue">could suffer</font> and we may not have the <font color="blue">resources available</font> to develop     these <font color="blue">products on</font> our own</td>
    </tr>
    <tr>
      <td>Certain of our partners are pursuing other <font color="blue">technologies</font> or developing other     drugs either on their own or in <font color="blue">collaboration with others</font>, including our     <font color="blue">competitors</font>, to develop <font color="blue">treatments</font> for the <font color="blue">same diseases targeted by</font> our own     <font color="blue">collaborative</font> programs</td>
    </tr>
    <tr>
      <td><font color="blue">Competition </font><font color="blue">may negatively impact</font> a partner’s focus     on and <font color="blue">commitment</font> to our drug and, as a result, <font color="blue">could delay</font> or otherwise     <font color="blue">negatively affect</font> the <font color="blue">commercialization</font> of our drug</td>
    </tr>
    <tr>
      <td>In addition, the <font color="blue">disappointing</font> results of the two Affinitak trials, our     Phase 3 <font color="blue"><font color="blue">clinical trial</font>s</font> of <font color="blue">alicaforsen</font> in <font color="blue"><font color="blue">patients with</font> active</font> Crohn’s     disease, or any <font color="blue">future <font color="blue">clinical trial</font> failures could impair</font> our ability to     attract  new  <font color="blue">collaborative</font>  partners</td>
    </tr>
    <tr>
      <td>If we <font color="blue">cannot continue</font> to secure     <font color="blue">additional</font> <font color="blue">collaborative</font> partners, our <font color="blue">revenues could decrease</font> and the     <font color="blue">development</font> of our drugs <font color="blue">could suffer</font></td>
    </tr>
    <tr>
      <td>If we <font color="blue">cannot protect</font> our patents or our <font color="blue">proprietary rights</font>, others may     compete more <font color="blue">directly against us</font></td>
    </tr>
    <tr>
      <td>Our <font color="blue">success depends</font> to a <font color="blue">significant</font> degree upon our ability to continue to     develop and <font color="blue">secure <font color="blue">intellectual</font> <font color="blue">property rights</font></font> to <font color="blue">proprietary products</font> and     services</td>
    </tr>
    <tr>
      <td>However, we may not receive <font color="blue"><font color="blue">issued patents</font> on</font> any of our pending     <font color="blue">patent <font color="blue"><font color="blue">application</font>s</font></font> in the <font color="blue">United States </font>or in other countries</td>
    </tr>
    <tr>
      <td>In addition,     the scope of any of our <font color="blue"><font color="blue">issued patents</font> may</font> not be <font color="blue">sufficiently broad</font> to     <font color="blue">provide us with</font> a <font color="blue">competitive advantage</font></td>
    </tr>
    <tr>
      <td>Furthermore, our <font color="blue">issued patents</font> or     patents  licensed to us may be <font color="blue">successfully</font> challenged, invalidated or     <font color="blue">circumvented</font>  so  that our <font color="blue">patent rights would</font> not create an <font color="blue">effective</font>     <font color="blue">competitive barrier</font> or <font color="blue">revenue source</font></td>
    </tr>
    <tr>
      <td><font color="blue">Intellectual </font><font color="blue"><font color="blue">property litigation</font> could</font> be expensive and <font color="blue">prevent us from</font>     pursuing our programs</td>
    </tr>
    <tr>
      <td>It is possible that in the future we may have to defend our <font color="blue">intellectual</font>     <font color="blue">property rights</font></td>
    </tr>
    <tr>
      <td>In the event of an <font color="blue">intellectual</font> property dispute, we may be     forced to litigate to defend our rights or assert <font color="blue">them against others</font></td>
    </tr>
    <tr>
      <td>Disputes could involve arbitration, litigation or <font color="blue">proceedings</font> declared by     the <font color="blue">United States </font>Patent and Trademark Office or the International Trade     Commission or foreign patent <font color="blue">authorities</font></td>
    </tr>
    <tr>
      <td><font color="blue">Intellectual </font><font color="blue">property litigation</font>     can be <font color="blue">extremely expensive</font>, and this expense, as well as the <font color="blue">consequences</font>     should we not prevail, could seriously harm our business</td>
    </tr>
    <tr>
      <td>If a <font color="blue">third party</font> claims that our products or <font color="blue">technology</font> infringe their     patents or other <font color="blue">intellectual</font> <font color="blue">property rights</font>, we may have to <font color="blue">discontinue</font> an     <font color="blue">important product</font> or product line, alter our products and processes, pay     <font color="blue">license fees</font> or <font color="blue">cease certain <font color="blue">activities</font></font></td>
    </tr>
    <tr>
      <td>We may not be able to obtain a     license to needed <font color="blue">intellectual</font> property on favorable terms, if at all</td>
    </tr>
    <tr>
      <td><font color="blue">There     </font>are many patents issued or applied for in the bio<font color="blue">technology</font> industry, and we     may not be aware of patents or <font color="blue"><font color="blue">application</font>s</font> held by others that relate to     our business</td>
    </tr>
    <tr>
      <td>This is <font color="blue">especially</font> true since <font color="blue">patent <font color="blue"><font color="blue">application</font>s</font></font> in the     <font color="blue">United States </font>are <font color="blue">filed confidentially</font></td>
    </tr>
    <tr>
      <td>Moreover, the validity and breadth     of bio<font color="blue">technology</font> patents involve complex legal and factual questions for     which important legal issues remain unresolved</td>
    </tr>
    <tr>
      <td>If we do not progress in our <font color="blue">programs as</font> anticipated, the price of our     <font color="blue">securities could decrease</font></td>
    </tr>
    <tr>
      <td>For planning purposes, we estimate the timing of a variety of clinical,     <font color="blue">regulatory</font> and other <font color="blue">milestones</font>, like when a <font color="blue">certain product candidate will</font>     enter the clinic, when we will complete a <font color="blue">clinical trial</font>, or when we will     file an <font color="blue">application</font> for <font color="blue">marketing approval</font></td>
    </tr>
    <tr>
      <td>We base our estimates on present     facts and a variety of <font color="blue">assumptions</font></td>
    </tr>
    <tr>
      <td>Many of the underlying <font color="blue">assumptions</font> are     outside of our control</td>
    </tr>
    <tr>
      <td>If we do not achieve       33     ______________________________________________________________________       <font color="blue">milestones</font> when we expect to, <font color="blue">investors could</font> be <font color="blue">disappointed</font> and the price     of our <font color="blue">securities would likely decrease</font></td>
    </tr>
    <tr>
      <td>The loss of <font color="blue">key personnel</font>, or the <font color="blue">inability</font> to attract and retain highly     skilled personnel, could make it more <font color="blue">difficult</font> to run our business and     reduce our likelihood of success</td>
    </tr>
    <tr>
      <td>We are <font color="blue">dependent on</font> the <font color="blue">principal members</font> of our <font color="blue">management</font> and scientific     staff</td>
    </tr>
    <tr>
      <td>We do not have <font color="blue">employment <font color="blue">agreements</font> with</font> any of our executive     officers</td>
    </tr>
    <tr>
      <td>The loss of our <font color="blue">management</font> and <font color="blue">key scientific employees might slow</font>     the <font color="blue">achievement</font> of <font color="blue">important research</font> and <font color="blue">development</font> goals</td>
    </tr>
    <tr>
      <td>It is also     critical to our success that we recruit and retain <font color="blue">qualified scientific</font>     personnel to perform research and <font color="blue">development</font> work</td>
    </tr>
    <tr>
      <td>We may not be able to     attract  and  retain  skilled  and experienced <font color="blue">scientific personnel on</font>     acceptable terms because of <font color="blue">intense <font color="blue">competition</font></font> for experienced <font color="blue">scientists</font>     among  many <font color="blue">pharmaceutical</font> and health care companies, universities and     non-profit research institutions</td>
    </tr>
    <tr>
      <td>Failure to succeed in <font color="blue"><font color="blue">clinical trial</font>s</font> may     make  it  more  <font color="blue">challenging</font> to recruit and retain <font color="blue">qualified scientific</font>     personnel</td>
    </tr>
    <tr>
      <td>If the price of our securities continues to be highly volatile, this could     make it harder for you to liquidate your <font color="blue">investment</font> and could increase your     risk of suffering a loss</td>
    </tr>
    <tr>
      <td>The <font color="blue">market price</font> of our <font color="blue">common stock</font>, like that of the securities of many     other bio<font color="blue"><font color="blue">pharmaceutical</font> companies</font>, has been and is likely to continue to be     highly  volatile</td>
    </tr>
    <tr>
      <td>These  <font color="blue">fluctuations</font>  in  our <font color="blue">common stock</font> price may     <font color="blue">significant</font>ly affect the <font color="blue">trading price</font> of our securities</td>
    </tr>
    <tr>
      <td>During the 12     months preceding <font color="blue">December </font>31, 2005, the <font color="blue">market price</font> of our <font color="blue">common stock</font>     ranged from dlra2dtta76 to dlra6dtta09 per share</td>
    </tr>
    <tr>
      <td><font color="blue">On February </font>17, 2006, the closing     price of our <font color="blue">common stock</font> on the <font color="blue">Nasdaq National Market </font>was dlra8dtta24</td>
    </tr>
    <tr>
      <td><font color="blue">Many     </font>factors  can affect the <font color="blue">market price</font> of our securities, including, for     example,  <font color="blue">fluctuations</font>  in  our  operating  results,  <font color="blue">announcements</font> of     <font color="blue">collaborations</font>, <font color="blue">clinical trial</font> results, <font color="blue">technological innovations</font> or new     products being developed by us or our <font color="blue">competitors</font>, <font color="blue">government</font>al regulation,     <font color="blue">regulatory</font> approval, <font color="blue">development</font>s in patent or other <font color="blue">proprietary rights</font>,     public  concern  regarding  the safety of our drugs and <font color="blue">general market</font>     <font color="blue">conditions</font></td>
    </tr>
    <tr>
      <td>If a natural or man-made disaster strikes our research and <font color="blue">development</font>     <font color="blue">facilities</font>, it <font color="blue">could delay</font> our progress developing and <font color="blue">commercializing</font> our     drugs or our TIGER <font color="blue"><font color="blue">biosensor</font> system</font></td>
    </tr>
    <tr>
      <td>We are developing our TIGER <font color="blue"><font color="blue">biosensor</font> system</font> in our <font color="blue">facility located</font> in     Carlsbad, California</td>
    </tr>
    <tr>
      <td>Additionally, we <font color="blue">manufacture</font> our research and clinical     supplies  in  a  separate  <font color="blue">manufacturing</font> <font color="blue">facility located</font> in Carlsbad,     California</td>
    </tr>
    <tr>
      <td>The <font color="blue">facilities</font> and the equipment we use to develop the <font color="blue">TIGER     </font><font color="blue"><font color="blue">biosensor</font> system</font> and <font color="blue">manufacture</font> our <font color="blue">drugs would</font> be costly to replace and     could require substantial lead time to repair or replace</td>
    </tr>
    <tr>
      <td>Either of our     <font color="blue">facilities</font>  may be harmed by natural or man-made disasters, including,     without <font color="blue">limitation</font>, <font color="blue">earthquakes</font>, floods and fires, and in the event they are     <font color="blue">affected by</font> a disaster, our <font color="blue">development</font> and <font color="blue">commercialization</font> efforts would     be delayed</td>
    </tr>
    <tr>
      <td>Although we possess insurance for damage to our property and the     <font color="blue">disruption</font>  of our business <font color="blue">from casualties</font>, this <font color="blue">insurance may</font> not be     sufficient to cover all of our <font color="blue">potential losses</font> and may not continue to be     available to us on acceptable terms, or at all</td>
    </tr>
    <tr>
      <td><font color="blue">Provisions  </font>in  our <font color="blue">certificate</font> of <font color="blue">incorporation</font>, other <font color="blue">agreements</font> and     <font color="blue">Delaware </font>law may prevent <font color="blue">stockholders</font> from receiving a premium for their     shares</td>
    </tr>
    <tr>
      <td>Our <font color="blue">certificate</font> of <font color="blue">incorporation</font> provides for <font color="blue">classified terms</font> for the     members of our board of <font color="blue">directors</font></td>
    </tr>
    <tr>
      <td>Our <font color="blue">certificate</font> also includes a provision     that requires at least 66prca of our voting <font color="blue">stockholders</font> to approve a merger or     certain other business <font color="blue">transaction</font>s with, or <font color="blue">proposed by</font>, any holder of 15prca     or more of our voting stock, except in cases where certain <font color="blue">directors</font> approve     the <font color="blue">transaction</font> or <font color="blue">certain minimum price criteria</font> and other procedural     <font color="blue">requirements</font> are met</td>
    </tr>
    <tr>
      <td>34     ______________________________________________________________________       Our <font color="blue">certificate</font> of <font color="blue">incorporation</font> also requires that any action required or     permitted to be taken by our <font color="blue">stockholders</font> must be taken at a duly called     annual or <font color="blue">special meeting</font> of <font color="blue">stockholders</font> and may not be <font color="blue">taken by written</font>     consent</td>
    </tr>
    <tr>
      <td>In addition, only our board of <font color="blue">directors</font>, chairman of the board or     <font color="blue">chief executive officer</font> can call <font color="blue">special meeting</font>s of our <font color="blue">stockholders</font></td>
    </tr>
    <tr>
      <td>We     also have implemented a <font color="blue">stockholders</font>’ rights plan, also called a poison     pill, <font color="blue">which could</font> make it uneconomical for a <font color="blue">third party</font> to acquire our     <font color="blue">company on</font> a <font color="blue">hostile basis</font></td>
    </tr>
    <tr>
      <td>These provisions, as well as <font color="blue">Delaware </font>law and     other of our <font color="blue">agreements</font>, may discourage certain types of <font color="blue">transaction</font>s in     which our <font color="blue">stockholders</font> might otherwise receive a premium for their shares     over  then  current  market  prices,  and may limit the ability of our     <font color="blue">stockholders</font> to approve <font color="blue">transaction</font>s that they think may be in their best     interests</td>
    </tr>
    <tr>
      <td>In addition, our board of <font color="blue">directors</font> has the authority to fix the     rights and <font color="blue">preferences</font> of and <font color="blue">issue shares</font> of preferred stock, which may     have the effect of delaying or preventing a change in control of our company     <font color="blue">without action by</font> our <font color="blue">stockholders</font></td>
    </tr>
    <tr>
      <td>If <font color="blue">registration rights</font> that we have <font color="blue">previously granted</font> are exercised, then     the price of our <font color="blue">securities may</font> be <font color="blue">negatively affect</font>ed</td>
    </tr>
    <tr>
      <td>We have granted <font color="blue">registration rights</font> to Lilly, which cover approximately 2dtta5     million  shares of our <font color="blue">common stock</font>, which we issued to Lilly upon the     <font color="blue">conversion</font> of <font color="blue">outstanding convertible securities</font></td>
    </tr>
    <tr>
      <td>We <font color="blue">also registered</font> for     resale 12cmam000cmam000 shares of our <font color="blue">common stock</font> and 2cmam999cmam998 shares of our     <font color="blue">common stock</font> issuable upon the exercise of warrants, which we issued as part     of our August 2005 private placement</td>
    </tr>
    <tr>
      <td>In addition, on <font color="blue">December </font>22, 2005, we     filed a Form S-3 <font color="blue">shelf registration statement with</font> the SEC to register up to     dlra200cmam000cmam000 worth of our <font color="blue">common stock</font> for possible issuance</td>
    </tr>
    <tr>
      <td>The addition     of these <font color="blue">shares into</font> the <font color="blue">market may</font> have an adverse effect on the price of     our securities</td>
    </tr>
    <tr>
      <td>Our business is subject to changing <font color="blue">regulations</font> for <font color="blue">corporate governance</font> and     public  <font color="blue">disclosure</font>  that  has <font color="blue">increased both</font> our costs and the risk of     <font color="blue">noncompliance</font></td>
    </tr>
    <tr>
      <td>Each year we are required to evaluate our internal controls systems in order     to allow <font color="blue">management</font> to report on, and our Independent Registered Public     Accounting  Firm  to  attest  to, our internal controls as required by     Section 404 of the Sarbanes-Oxley Act</td>
    </tr>
    <tr>
      <td>As a result, we will incur <font color="blue">additional</font>     expenses and will suffer a diversion of <font color="blue">management</font>’s time</td>
    </tr>
    <tr>
      <td>In addition, if     we <font color="blue">cannot continue</font> to <font color="blue">comply with</font> the <font color="blue">requirements</font> of Section 404 in a     timely  manner,  we  might be subject to sanctions or <font color="blue">investigation by</font>     <font color="blue">regulatory</font> <font color="blue">authorities</font>, such as the Securities and Exchange Commission, the     Public Company Accounting Oversight Board (PCAOB), or the NASDAQ Stock     Exchange</td>
    </tr>
    <tr>
      <td>Any <font color="blue">such action could adversely affect</font> our financial results and     the <font color="blue">market price</font> of our <font color="blue">common stock</font></td>
    </tr>
    <tr>
      <td><font color="blue">Risks Associated </font>with our Drug Discovery and Development Business       If  we or our <font color="blue">partners fail</font> to obtain <font color="blue">regulatory</font> approval for our drug     <font color="blue">candidates</font>, we will not be able to sell them</td>
    </tr>
    <tr>
      <td>We  and our partners <font color="blue">must conduct</font> time-consuming, extensive and costly     <font color="blue"><font color="blue">clinical trial</font>s</font> to show the safety and efficacy of each of our drugs before     a drug can be approved for sale</td>
    </tr>
    <tr>
      <td>We <font color="blue">must conduct</font> these trials in compliance     with  United  States Food and Drug Administration <font color="blue">regulations</font> and with     comparable <font color="blue">regulations</font> in other countries</td>
    </tr>
    <tr>
      <td><font color="blue">If the FDA </font>or another <font color="blue">regulatory</font>     agency believes that we or our partners have not <font color="blue">sufficiently <font color="blue">demonstrate</font>d</font>     the  safety or efficacy of our drugs, it will not <font color="blue">approve them</font> or will     require <font color="blue">additional</font> studies, which can be time consuming and expensive and     which will delay <font color="blue">commercialization</font> of a drug</td>
    </tr>
    <tr>
      <td>We and our partners may not be     able to obtain <font color="blue">necessary</font> <font color="blue">regulatory</font> approvals on a timely basis, if at all,     for any of our drugs</td>
    </tr>
    <tr>
      <td>Failure to receive these approvals or delays in these     approvals could prevent or delay commercial <font color="blue">introduction</font> of a product and,     as a result, <font color="blue">could negatively impact</font> our ability to <font color="blue">generate revenue from</font>     product  sales</td>
    </tr>
    <tr>
      <td>In addition, following approval of a drug, we and our     partners must <font color="blue">comply with</font> comprehensive <font color="blue">government</font> <font color="blue">regulations</font> regarding how     we <font color="blue">manufacture</font>, market and <font color="blue">distribute <font color="blue">drug products</font></font></td>
    </tr>
    <tr>
      <td>If we fail to comply     with these <font color="blue">regulations</font>, regulators       35     ______________________________________________________________________       <font color="blue">could force us</font> to withdraw a drug from the market or impose other penalties     or <font color="blue">requirements</font> that also could have a <font color="blue">negative impact on</font> our financial     results</td>
    </tr>
    <tr>
      <td>We have <font color="blue">only introduced one commercial drug product</font>, Vitravene</td>
    </tr>
    <tr>
      <td>We cannot     guarantee that any of our other <font color="blue">drugs will</font> be safe and <font color="blue">effective</font>, will be     approved for <font color="blue">commercialization</font> or that our partners or we can <font color="blue">successfully</font>     <font color="blue">commercialize</font> these drugs</td>
    </tr>
    <tr>
      <td>If the results of clinical testing indicate that any of our <font color="blue">drugs under</font>     <font color="blue">development</font> are not suitable for <font color="blue">commercial use</font>, or if <font color="blue">additional</font> testing is     required to <font color="blue"><font color="blue">demonstrate</font> suitability</font>, we may need to <font color="blue">abandon one</font> or more of     our drug <font color="blue">development</font> programs</td>
    </tr>
    <tr>
      <td>Drug <font color="blue">discovery</font> and <font color="blue">development</font> has inherent risks, including the risk that     <font color="blue">molecular targets prove</font> not to be important in a <font color="blue">particular disease</font>; the     risk that compounds that <font color="blue">demonstrate</font> attractive activity in preclinical     studies do not <font color="blue">demonstrate</font> similar activity in <font color="blue">human beings</font>; the risk that a     compound is not safe or <font color="blue">effective</font> for use in humans; and the risk that     successful results in early human <font color="blue"><font color="blue">clinical trial</font>s</font> may not be <font color="blue">indicative</font> of     results in late-stage <font color="blue"><font color="blue">clinical trial</font>s</font></td>
    </tr>
    <tr>
      <td><font color="blue">Antisense </font><font color="blue">technology</font> in particular is     <font color="blue">relatively new</font> and unproven</td>
    </tr>
    <tr>
      <td>We are <font color="blue">applying most</font> of our resources to create     safe and <font color="blue">effective</font> drugs for human use</td>
    </tr>
    <tr>
      <td>Any of the <font color="blue">risks described</font> above     could <font color="blue">prevent us from</font> meeting this goal</td>
    </tr>
    <tr>
      <td>In  March 2003, we reported the results of a Phase 3 <font color="blue">clinical trial</font> of     Affinitak in <font color="blue">patients with</font> late stage non-small cell lung cancer and in     October 2004, we reported the results of a second similar Phase 3 clinical     trial</td>
    </tr>
    <tr>
      <td>In each case, Affinitak failed to <font color="blue">demonstrate</font> improved survival     <font color="blue">sufficient enough</font> to support an NDA filing</td>
    </tr>
    <tr>
      <td>In <font color="blue">December </font>2004, we reported     the results of our Phase 3 <font color="blue"><font color="blue">clinical trial</font>s</font> of <font color="blue">alicaforsen</font> in <font color="blue">patients with</font>     active  Crohn’s  disease,  in  which  <font color="blue">alicaforsen</font>  did not <font color="blue">demonstrate</font>     statistically <font color="blue">significant</font> induction of <font color="blue">clinical remissions compared</font> to     placebo</td>
    </tr>
    <tr>
      <td>If     any of our drugs in <font color="blue">clinical studies</font> do not <font color="blue">show sufficient efficacy</font> in     patients  with the <font color="blue">targeted indication</font>, it <font color="blue">could negatively impact</font> our     <font color="blue">development</font> and <font color="blue">commercialization</font> goals for this and other drugs and our     <font color="blue">stock price could decline</font></td>
    </tr>
    <tr>
      <td>Our <font color="blue">success will depend upon</font> the medical <font color="blue">community</font>, patients and third-party     <font color="blue">payers accepting</font> our products as medically useful, cost-<font color="blue">effective</font> and safe</td>
    </tr>
    <tr>
      <td>We <font color="blue">cannot guarantee</font> that, if approved for <font color="blue">commercialization</font>, doctors will     use our products to <font color="blue">treat patients</font></td>
    </tr>
    <tr>
      <td>We currently have <font color="blue">one <font color="blue">commercially</font></font>     <font color="blue">available drug product</font>, Vitravene, a treatment for <font color="blue">cytomegalovirus</font>, or CMV,     retinitis in AIDS patients, which addresses a small market</td>
    </tr>
    <tr>
      <td>Our partners and     we may not <font color="blue">successfully</font> <font color="blue">commercialize</font> <font color="blue">additional</font> products</td>
    </tr>
    <tr>
      <td>The degree of <font color="blue">market <font color="blue">acceptance</font></font> for any of our <font color="blue">products depends upon</font> a     number of factors, including:       ·        The receipt and scope of <font color="blue">regulatory</font> approvals;       ·        The <font color="blue">establishment</font> and <font color="blue">demonstration</font> in the medical and patient     <font color="blue">community</font>  of the efficacy and safety of our drugs and their potential     <font color="blue">advantages over competing products</font>;       ·        The cost and <font color="blue">effective</font>ness of our <font color="blue">drugs compared</font> to other available     therapies;       ·        The <font color="blue">patient convenience</font> of the <font color="blue">dosing regimen</font> for our drugs; and       ·        <font color="blue">Reimbursement </font>policies of <font color="blue">government</font> and <font color="blue">third party</font> payers</td>
    </tr>
    <tr>
      <td>Based on the profile of our drugs, physicians, patients, patient advocates,     payers  or the medical <font color="blue">community</font> in <font color="blue">general may</font> not accept and use any     products that we may develop</td>
    </tr>
    <tr>
      <td>36     ______________________________________________________________________       If we cannot <font color="blue">manufacture</font> our <font color="blue">drug products</font> or <font color="blue">contract with</font> a <font color="blue">third party</font> to     <font color="blue">manufacture</font> our <font color="blue">drug products</font> at costs that allow us to <font color="blue">charge competitive</font>     prices to buyers, we will not be able to <font color="blue">market products profitably</font></td>
    </tr>
    <tr>
      <td>If we <font color="blue">successfully</font> <font color="blue">commercialize</font> any of our drugs, we may be required to     establish large-scale commercial <font color="blue">manufacturing</font> capabilities</td>
    </tr>
    <tr>
      <td>In addition, as     our drug <font color="blue">development</font> pipeline increases and matures, we will have a greater     need for <font color="blue">clinical trial</font> and <font color="blue">commercial <font color="blue">manufacturing</font> capacity</font></td>
    </tr>
    <tr>
      <td>We have     limited experience <font color="blue">manufacturing</font> <font color="blue">pharmaceutical</font> products of the chemical     class <font color="blue">represented by</font> our drugs, called oligonucleotides, on a commercial     scale for the <font color="blue">systemic administration</font> of a drug</td>
    </tr>
    <tr>
      <td>There are a small number of     suppliers for <font color="blue">certain capital equipment</font> and <font color="blue">raw materials</font> that we use to     <font color="blue">manufacture</font> our drugs, and some of these <font color="blue">suppliers will</font> need to increase     their  scale  of production to meet our projected needs for commercial     <font color="blue">manufacturing</font></td>
    </tr>
    <tr>
      <td>Further, we <font color="blue">must continue</font> to improve our <font color="blue">manufacturing</font>     processes to allow us to reduce our <font color="blue">product costs</font></td>
    </tr>
    <tr>
      <td>We may not be able to     <font color="blue">manufacture</font>  at a cost or in quantities <font color="blue">necessary</font> to make <font color="blue">commercially</font>     <font color="blue">successful products</font></td>
    </tr>
    <tr>
      <td>Also, <font color="blue">manufacture</font>rs, including us, must adhere to the FDA’s current Good     Manufacturing Practices <font color="blue">regulations</font> which the FDA <font color="blue">enforces through</font> its     <font color="blue">facilities</font> inspection program</td>
    </tr>
    <tr>
      <td>We and our contract <font color="blue">manufacture</font>rs may not be     able to comply or maintain compliance with <font color="blue">Good Manufacturing Practices     </font><font color="blue">regulations</font></td>
    </tr>
    <tr>
      <td>Non-compliance  could <font color="blue">significant</font>ly delay our receipt of     <font color="blue">marketing approval</font> for <font color="blue">potential product</font>s or result in FDA <font color="blue">enforcement</font>     action  after  approval that <font color="blue">could limit</font> the <font color="blue">commercial success</font> of our     <font color="blue">potential product</font></td>
    </tr>
    <tr>
      <td>If our drug <font color="blue">discovery</font> and <font color="blue">development</font> business fails to compete <font color="blue">effective</font>ly,     our <font color="blue">drugs will</font> not contribute <font color="blue">significant</font> revenues</td>
    </tr>
    <tr>
      <td>Our <font color="blue">competitors</font> are engaged in all areas of drug <font color="blue">discovery</font> throughout the     world,  are  numerous, and include, among others, major <font color="blue">pharmaceutical</font>     companies and specialized bio<font color="blue">pharmaceutical</font> firms</td>
    </tr>
    <tr>
      <td>Other companies are     engaged in developing antisense <font color="blue">technology</font> or <font color="blue">unique methods</font> of identifying     <font color="blue"><font color="blue">infectious organism</font>s</font></td>
    </tr>
    <tr>
      <td>Our <font color="blue">competitors</font> may succeed in developing drugs or     <font color="blue">technologies</font> that are more <font color="blue">effective</font> than any drugs or <font color="blue">technologies</font> that we     are developing</td>
    </tr>
    <tr>
      <td>These competitive <font color="blue">development</font>s could make our products     obsolete or non-competitive</td>
    </tr>
    <tr>
      <td>Many of our <font color="blue">competitors</font> have <font color="blue">substantially</font> greater financial, technical and     human resources than we do</td>
    </tr>
    <tr>
      <td>In addition, many of these <font color="blue">competitors</font> have     <font color="blue">significant</font>ly  greater experience than we do in <font color="blue">conducting preclinical</font>     testing and human <font color="blue"><font color="blue">clinical trial</font>s</font> of new <font color="blue">pharmaceutical</font> products and in     obtaining FDA and other <font color="blue">regulatory</font> approvals of products for use in health     care</td>
    </tr>
    <tr>
      <td>Accordingly, our <font color="blue">competitors</font> may succeed in obtaining <font color="blue">regulatory</font>     approval for <font color="blue">products earlier than</font> we do</td>
    </tr>
    <tr>
      <td>We <font color="blue">will also compete with respect</font>     to marketing and sales capabilities, areas in which we have limited or no     experience</td>
    </tr>
    <tr>
      <td>We <font color="blue">depend on</font> <font color="blue">third parties</font> in the conduct of our <font color="blue"><font color="blue">clinical trial</font>s</font> for our     product  <font color="blue">candidates</font>  and any failure of those parties to fulfill their     <font color="blue">obligations</font> could adversely affect our <font color="blue">development</font> and <font color="blue">commercialization</font>     plans</td>
    </tr>
    <tr>
      <td>We  depend  on  independent  clinical <font color="blue">investigators</font>, contract research     <font color="blue">organizations</font> and other <font color="blue">third party</font> service providers in the conduct of our     <font color="blue"><font color="blue">clinical trial</font>s</font> for our product <font color="blue">candidates</font> and expect to continue to do so     in the future</td>
    </tr>
    <tr>
      <td>We <font color="blue">rely heavily on</font> these parties for <font color="blue">successful execution</font> of     our <font color="blue"><font color="blue">clinical trial</font>s</font>, but do not control many aspects of their <font color="blue">activities</font></td>
    </tr>
    <tr>
      <td>For  example, the <font color="blue">investigators</font> are not our employees</td>
    </tr>
    <tr>
      <td>However, we are     responsible for ensuring that each of our <font color="blue"><font color="blue">clinical trial</font>s</font> is conducted in     <font color="blue">accordance with</font> the <font color="blue">general investigational</font> plan and protocols for the     trial</td>
    </tr>
    <tr>
      <td>Third <font color="blue">parties may</font> not complete <font color="blue">activities</font> on schedule, or may not     conduct our <font color="blue"><font color="blue">clinical trial</font>s</font> in <font color="blue">accordance with</font> <font color="blue">regulatory</font> <font color="blue">requirements</font> or     our stated protocols</td>
    </tr>
    <tr>
      <td>The failure of these <font color="blue">third parties</font> to carry out their     <font color="blue">obligations</font>  could  delay  or  prevent  the  <font color="blue">development</font>, approval and     <font color="blue">commercialization</font> of our product <font color="blue">candidates</font></td>
    </tr>
    <tr>
      <td>37     ______________________________________________________________________       <font color="blue">Risks Associated </font>with our Ibis Division       We may not <font color="blue">successfully</font> develop or <font color="blue">derive <font color="blue">revenues from</font></font> our business based     on our TIGER <font color="blue"><font color="blue">biosensor</font> system</font></td>
    </tr>
    <tr>
      <td><font color="blue">Our TIGER </font><font color="blue"><font color="blue">biosensor</font> system</font> is subject to the <font color="blue">risks inherent</font> in developing     tools <font color="blue">based on</font> innovative <font color="blue">technologies</font></td>
    </tr>
    <tr>
      <td>Our product is at an <font color="blue">early stage</font> of     <font color="blue">development</font>  and requires <font color="blue">additional</font> research and <font color="blue">development</font> prior to     marketing</td>
    </tr>
    <tr>
      <td>If our <font color="blue">potential customers fail</font> to purchase our TIGER <font color="blue">biosensor</font>     system  due  to <font color="blue">competition</font> or other factors, or if we fail to develop     <font color="blue"><font color="blue">application</font>s</font> that lead to <font color="blue">market <font color="blue">acceptance</font></font>, we <font color="blue">could lose</font> our <font color="blue">investment</font> in     this <font color="blue">technology</font> and our TIGER business could fail to meet our business and     <font color="blue">financial <font color="blue">objectives</font></font></td>
    </tr>
    <tr>
      <td>If we fail to <font color="blue">secure commercial partners</font> for our TIGER <font color="blue"><font color="blue">biosensor</font> system</font>, our     <font color="blue">commercialization</font> efforts for our TIGER <font color="blue">biosensor</font> may be harmed or delayed</td>
    </tr>
    <tr>
      <td>We expect to <font color="blue">depend on</font> <font color="blue">third parties</font> to <font color="blue">commercialize</font> our TIGER <font color="blue">biosensor</font>     system, particularly in the areas of <font color="blue">manufacturing</font>, selling and servicing     the <font color="blue">instruments</font></td>
    </tr>
    <tr>
      <td>In addition, we expect to <font color="blue">depend on</font> <font color="blue">third parties</font> to sell     and distribute our <font color="blue">infectious organism</font> ID kits to non-<font color="blue">government</font> customers     in  the healthcare-associated infection control and <font color="blue">infectious disease</font>     <font color="blue"><font color="blue">diagnostic</font> markets</font></td>
    </tr>
    <tr>
      <td>If we are unable to reach <font color="blue">agreements</font> with suitable third     parties, we may fail to meet our business <font color="blue">objectives</font> for the TIGER <font color="blue">biosensor</font>     system</td>
    </tr>
    <tr>
      <td>We may not <font color="blue">successfully</font> establish a <font color="blue">distribution</font>, <font color="blue">manufacturing</font>,     sale or <font color="blue">service relationship</font> or be able to make alternative <font color="blue">arrangements</font></td>
    </tr>
    <tr>
      <td>Moreover, these <font color="blue">relationships may</font> not succeed, may require us to give up a     part of our <font color="blue">ownership interest</font>, or <font color="blue">may diminish</font> our <font color="blue">profit margins on</font> our     TIGER <font color="blue">instruments</font> and ID kits</td>
    </tr>
    <tr>
      <td>We <font color="blue">depend on</font> <font color="blue">government</font> contracts for most of our revenues and the loss of     <font color="blue">government</font>  contracts  or  a  decline in funding of existing or future     <font color="blue">government</font> contracts could adversely affect our revenues and <font color="blue">cash flows</font> and     our ability to fund our growth</td>
    </tr>
    <tr>
      <td><font color="blue">Virtually </font>all of our TIGER business’ revenue is from the sale of services     and products to the <font color="blue">United States </font><font color="blue">government</font></td>
    </tr>
    <tr>
      <td>The US <font color="blue">government</font> may cancel     these contracts at any time <font color="blue">without penalty</font> or may change its <font color="blue">requirements</font>,     programs or <font color="blue">contract budget</font> or decline to <font color="blue">exercise option periods</font>, any of     which  could  reduce  our revenues and <font color="blue">cash flows</font> from US <font color="blue">government</font>     contracts</td>
    </tr>
    <tr>
      <td>Our revenues and <font color="blue">cash flow from</font> US <font color="blue">government</font> contracts could     also be <font color="blue">reduced by declines</font> in US defense, homeland security and other     <font color="blue">federal agency budgets</font></td>
    </tr>
    <tr>
      <td>For the three months and fiscal year ended <font color="blue">December </font>31, 2005, Isis derived     approximately 21prca and 30prca, respectively, of its <font color="blue">revenue from agencies</font> of the     <font color="blue">United States </font><font color="blue">government</font>, including through our sub<font color="blue">contract with</font> SAIC     Because of the <font color="blue">concentration</font> of our contracts, we are vulnerable to adverse     changes in our revenues and <font color="blue">cash flows</font> if a <font color="blue">significant</font> number of our United     States Government contracts and <font color="blue">subcontracts</font> are <font color="blue">simultaneously delayed</font> or     canceled  for <font color="blue">budgetary performance</font> or other reasons</td>
    </tr>
    <tr>
      <td>If <font color="blue">United States </font>    defense and other <font color="blue">federal agencies choose</font> to reduce their <font color="blue">purchases under</font>     our contracts, exercise their right to terminate contracts, fail to exercise     options to <font color="blue">re<font color="blue">new contract</font>s</font> or limit our ability to obtain <font color="blue">new contract</font>     awards, our revenues and <font color="blue">cash flows</font> could be <font color="blue">adversely affected</font></td>
    </tr>
    <tr>
      <td>We may be liable for <font color="blue">penalties under</font> a variety of <font color="blue">procurement rules</font> and     <font color="blue">regulations</font>, and changes in <font color="blue">government</font> <font color="blue">regulations</font> could adversely impact     our revenues, operating expenses and operating margins</td>
    </tr>
    <tr>
      <td>Under our <font color="blue">agreements</font> with the <font color="blue">United States </font><font color="blue">government</font>, we must <font color="blue">comply with</font>     and are <font color="blue">affected by</font> various <font color="blue">government</font> <font color="blue">regulations</font> that impact our operating     costs, operating margins and our <font color="blue">internal organization</font> and operation of our     <font color="blue">businesses</font></td>
    </tr>
    <tr>
      <td>These <font color="blue">regulations</font> affect how our customers and Isis do business     and, in some instances, impose added costs on our <font color="blue">businesses</font></td>
    </tr>
    <tr>
      <td>Any changes in     <font color="blue">applicable laws could adversely affect</font> the <font color="blue">financial performance</font> of our     TIGER business</td>
    </tr>
    <tr>
      <td>With respect to US <font color="blue">government</font>       38     ______________________________________________________________________       contracts,  any failure to <font color="blue">comply with</font> applicable laws could result in     contract termination, price or <font color="blue">fee reductions</font> or suspension or <font color="blue">debarment</font>     from  <font color="blue">contracting with</font> the US <font color="blue">government</font></td>
    </tr>
    <tr>
      <td>Among the most <font color="blue">significant</font>     <font color="blue">regulations</font> are the following:       ·        the US Federal Acquisition Regulations, which comprehensively     regulate  the  formation, administration and performance of <font color="blue">government</font>     contracts;       ·        the US Truth in Negotiations Act, which requires <font color="blue">certification</font>     and <font color="blue">disclosure</font> of all cost and <font color="blue">pricing data</font> in <font color="blue">connection with</font> contract     <font color="blue">negotiations</font>; and       ·         the  US Cost Accounting Standards, <font color="blue">which impose accounting</font>     <font color="blue">requirements</font> that govern our right to reimbursement under certain cost-based     <font color="blue">government</font> contracts</td>
    </tr>
    <tr>
      <td>If  our  TIGER  <font color="blue">biosensor</font>  system’s  <font color="blue">reliability</font>  does not <font color="blue">meet market</font>     <font color="blue">expectations</font>, we may be unable to retain our <font color="blue">existing customers</font> and attract     <font color="blue">new customers</font></td>
    </tr>
    <tr>
      <td>Complex <font color="blue">diagnostic</font> <font color="blue">instruments</font> such as our TIGER <font color="blue"><font color="blue">biosensor</font> system</font> typically     require operating and <font color="blue">reliability</font> <font color="blue">improvements</font> following their initial     <font color="blue">introduction</font></td>
    </tr>
    <tr>
      <td>As we continue to develop our TIGER <font color="blue"><font color="blue">biosensor</font> system</font> and its     related <font color="blue"><font color="blue">application</font>s</font> we will need to make sure our customers are satisfied     with the sensor’s <font color="blue">reliability</font></td>
    </tr>
    <tr>
      <td>Our efforts to satisfy our customer’s needs     for instrument <font color="blue">reliability</font> could result in <font color="blue">greater than</font> anticipated service     expenses or divert other resources</td>
    </tr>
    <tr>
      <td>Additionally, if we fail to resolve     <font color="blue">reliability</font>  issues  as  they  develop, we could <font color="blue">materially</font> damage our     reputation <font color="blue">which could</font> <font color="blue">prevent us from</font> retaining our <font color="blue">existing customers</font> and     attracting <font color="blue">new customers</font></td>
    </tr>
    <tr>
      <td>If we had to replace a supplier of one of the <font color="blue">major hardware components</font> of     our TIGER <font color="blue"><font color="blue">biosensor</font> system</font>, it <font color="blue">could delay</font> our <font color="blue">commercialization</font> efforts and     lengthen our <font color="blue">sales cycle</font></td>
    </tr>
    <tr>
      <td>We have a <font color="blue">single supplier</font> for <font color="blue">each major hardware</font> component of our <font color="blue">TIGER     </font><font color="blue">biosensor</font>  system</td>
    </tr>
    <tr>
      <td>Although,  we  believe  we would be able to find a     <font color="blue">replacement provider</font>, if any of these <font color="blue">suppliers stopped providing us with</font>     their <font color="blue">respective components</font>, identifying and securing a <font color="blue">suitable replacement</font>     <font color="blue">could delay</font> our <font color="blue">commercialization</font> efforts and lengthen our <font color="blue">sales cycle</font></td>
    </tr>
    <tr>
      <td>If our TIGER business fails to compete <font color="blue">effective</font>ly, it may not succeed or     contribute <font color="blue">significant</font> revenues</td>
    </tr>
    <tr>
      <td>Many of our <font color="blue">competitors</font> have, and in the future these and other <font color="blue">competitors</font>     may have, <font color="blue">significant</font>ly greater financial, marketing, sales, <font color="blue">manufacturing</font>,     <font color="blue">distribution</font> and <font color="blue">technological resources than us</font></td>
    </tr>
    <tr>
      <td>Moreover, these companies     may have <font color="blue">substantially</font> greater expertise in conducting <font color="blue"><font color="blue">clinical trial</font>s</font> and     research and <font color="blue">development</font>, greater ability to obtain <font color="blue">necessary</font> <font color="blue">intellectual</font>     <font color="blue">property licenses</font> and greater brand <font color="blue">recognition than</font> we do</td>
    </tr>
    <tr>
      <td>In addition, our     <font color="blue">competitors</font>  may  be in better a position to respond quickly to new or     emerging <font color="blue">technologies</font>, may be able to undertake more extensive marketing     <font color="blue">campaigns</font>,  may adopt more <font color="blue">aggressive pricing policies</font> and may be more     successful  in attracting potential customers, employees and strategic     <font color="blue">partners than</font> we are</td>
    </tr>
    <tr>
      <td>The <font color="blue"><font color="blue">diagnostic</font>s industry</font> is <font color="blue">highly competitive</font></td>
    </tr>
    <tr>
      <td>Currently, large reference     laboratories, public health laboratories and hospitals perform the majority     of <font color="blue"><font color="blue">diagnostic</font> tests used by physicians</font> and other <font color="blue">health care providers</font></td>
    </tr>
    <tr>
      <td>We     expect that these <font color="blue">laboratories will compete vigorously</font> to maintain their     dominance in the <font color="blue"><font color="blue">diagnostic</font> testing market</font></td>
    </tr>
    <tr>
      <td>In order to achieve market     <font color="blue">acceptance</font> of our TIGER <font color="blue"><font color="blue">biosensor</font> system</font>, we will be required to <font color="blue">demonstrate</font>     that it provides accurate, cost-<font color="blue">effective</font> and/or time <font color="blue">saving alternatives</font> to     tests performed by traditional laboratory procedures and products made by     our <font color="blue">competitors</font></td>
    </tr>
    <tr>
      <td>39     ______________________________________________________________________       <font color="blue">Improvements </font>in preventing major diseases <font color="blue">could reduce</font> the need for our     TIGER <font color="blue">biosensor</font> <font color="blue">instruments</font> and ID kits, which in turn <font color="blue">could reduce</font> our     revenues</td>
    </tr>
    <tr>
      <td>We expect to derive a <font color="blue">significant</font> portion of our <font color="blue">revenues from</font> the sale of     the <font color="blue">infectious organism</font> ID kits <font color="blue">necessary</font> to use our TIGER <font color="blue"><font color="blue">biosensor</font> system</font></td>
    </tr>
    <tr>
      <td>The need to quickly identify and contain major threats, such as the avian     flu,  could  increase  the demand for our <font color="blue">infectious organism</font> ID kits</td>
    </tr>
    <tr>
      <td>Conversely,  <font color="blue">improvements</font>  in containing or treating a threat, such as     vaccines, would <font color="blue">significant</font>ly reduce the need to identify and contain the     threat</td>
    </tr>
    <tr>
      <td>Any reduction in the need to identify or contain a <font color="blue">threat could</font>     diminish the need for our <font color="blue">infectious organism</font> ID kits, <font color="blue">which could</font> reduce     our revenues</td>
    </tr>
    <tr>
      <td>If we <font color="blue">cannot access</font> or <font color="blue">license rights</font> to <font color="blue">particular nucleic acid sequences</font>     for <font color="blue">targeted diseases</font> in the future, we may be limited in our ability to     develop <font color="blue">new products</font> and <font color="blue">access new markets</font></td>
    </tr>
    <tr>
      <td><font color="blue">Although  </font>our <font color="blue">research staff seeks</font> to <font color="blue">discover particular</font> nucleic acid     sequences for <font color="blue">targeted diseases</font>, our ability to offer <font color="blue">diagnostic</font> tests for     diseases may <font color="blue">depend on</font> the ability of <font color="blue">third parties</font> to <font color="blue">discover particular</font>     sequences or markers and correlate them with disease, as well as the rate at     <font color="blue">which such <font color="blue">discoveries</font></font> are made</td>
    </tr>
    <tr>
      <td>Our ability to <font color="blue">design products</font> that target     these diseases may <font color="blue">depend on</font> our ability to obtain the <font color="blue">necessary</font> access to     <font color="blue">raw materials</font> or <font color="blue">intellectual</font> <font color="blue">property rights</font> from <font color="blue">third parties</font> who make     any of these <font color="blue">discoveries</font></td>
    </tr>
    <tr>
      <td>If we are unable to access new <font color="blue">technologies</font> or the     rights  to  particular  sequences  or markers <font color="blue">necessary</font> for <font color="blue">additional</font>     <font color="blue">diagnostic</font> <font color="blue">products on</font> <font color="blue">commercially</font> reasonable terms, we may not be able to     develop <font color="blue">new <font color="blue">diagnostic</font> products</font> or <font color="blue">enter new markets</font></td>
    </tr>
    <tr>
      <td>The <font color="blue">sales cycle</font>s for our TIGER <font color="blue">biosensor</font>s systems are lengthy, and we may     expend  substantial  funds  and <font color="blue">management</font> effort with no assurance of     <font color="blue">successfully</font> selling our TIGER <font color="blue">biosensor</font>s systems or services</td>
    </tr>
    <tr>
      <td>The <font color="blue">sales cycle</font>s for TIGER <font color="blue"><font color="blue">biosensor</font> system</font>s are <font color="blue">typically lengthy</font></td>
    </tr>
    <tr>
      <td>Our     sales and <font color="blue">licensing efforts</font>, and those of our partners, will  require the     <font color="blue">effective</font> <font color="blue">demonstration</font> of the benefits, value, and <font color="blue">differentiation</font> and     <font color="blue">validation</font>  of  our products and services, and <font color="blue">significant</font> training of     <font color="blue">multiple personnel</font> and <font color="blue">departments within</font> a <font color="blue">potential customer organization</font></td>
    </tr>
    <tr>
      <td>We or our partners may be required to negotiate <font color="blue">agreements</font> containing terms     unique to each prospective customer or licensee which would lengthen the     <font color="blue">sales cycle</font></td>
    </tr>
    <tr>
      <td>We may expend substantial funds and <font color="blue">management</font> effort with no     assurance that we will sell our products</td>
    </tr>
    <tr>
      <td>In addition, this <font color="blue">lengthy sales</font>     cycle makes it more <font color="blue">difficult</font> for us to <font color="blue">accurately forecast revenue</font> in     future  periods  and  may cause revenues and operating results to vary     <font color="blue">significant</font>ly in <font color="blue">future periods</font></td>
    </tr>
    <tr>
      <td>If we or our partners are required to obtain <font color="blue">regulatory</font> approval for our     TIGER  <font color="blue">biosensor</font>  system  <font color="blue"><font color="blue">application</font>s</font>, we may not <font color="blue">successfully</font> obtain     approval</td>
    </tr>
    <tr>
      <td><font color="blue">Depending  </font>on  their  <font color="blue">intended use</font>, our TIGER <font color="blue"><font color="blue">biosensor</font> system</font>s may be     <font color="blue">regulated as medical</font> device by the FDA and comparable agencies of other     countries and require <font color="blue">either premarket approval</font> (PMA) or 510(k) clearance     from the FDA, prior to marketing</td>
    </tr>
    <tr>
      <td>The 510(k) clearance process usually takes     from  three to twelve months from submission, but can take longer</td>
    </tr>
    <tr>
      <td>The     <font color="blue">premarket approval process</font> is much more costly, lengthy, uncertain and     <font color="blue">generally</font> takes <font color="blue">from six months</font> to two years or <font color="blue">longer from submission</font></td>
    </tr>
    <tr>
      <td>In     addition, <font color="blue">commercialization</font> of any <font color="blue">diagnostic</font> or other product that our     licensees  or <font color="blue">collaborators</font> or we develop <font color="blue">would depend upon successful</font>     <font color="blue">completion</font> of <font color="blue">preclinical testing</font> and <font color="blue"><font color="blue">clinical trial</font>s</font></td>
    </tr>
    <tr>
      <td><font color="blue">Preclinical </font>testing     and <font color="blue"><font color="blue">clinical trial</font>s</font> are long, expensive and <font color="blue">uncertain processes</font>, and we do     not know whether we, our licensees or any of our <font color="blue">collaborators</font>, would be     permitted or able to undertake <font color="blue"><font color="blue">clinical trial</font>s</font> of any <font color="blue">potential product</font>s</td>
    </tr>
    <tr>
      <td>It     may take us or our licensees or <font color="blue">collaborators</font> many years to complete any     <font color="blue">such testing</font>, and <font color="blue">failure could</font> occur at any stage</td>
    </tr>
    <tr>
      <td><font color="blue">Preliminary </font>results of     trials do not <font color="blue">necessarily predict final</font> results, and acceptable results in     <font color="blue">early trials may</font> not be repeated in <font color="blue">later trials</font></td>
    </tr>
    <tr>
      <td>We or our <font color="blue">collaborators</font>     may encounter delays or <font color="blue">rejections</font> of <font color="blue">potential product</font>s may be <font color="blue">encountered</font>     <font color="blue">based on</font> changes in       40     ______________________________________________________________________       <font color="blue">regulatory</font>  policy  for  product approval during the period of product     <font color="blue">development</font> and <font color="blue">regulatory</font> agency review</td>
    </tr>
  </tbody>
</table>